EGFR-Positive NSCLC: Role of Biopsy and Molecular Testing in Determining Therapeutic Selection
Jointly provided by Postgraduate Institute for Medicine and Enquiring Minds.
This activity is supported by an independent education grant from Astellas and Boehringer Ingelheim.
Scroll to the Bottom of this Information to Begin this Course
Release date: January 30, 2016
Valid through: March 30, 2017
Specialty: Oncologists, radiologists
Estimated Time to Complete Activity: 60 minutes
This activity has been designed to meet the educational needs of oncologists, pathologists, radiologists, and other members of the oncology care team who have an interest in NSCLC.
Upon completion of this activity, participants should be better able to:
- Outline criteria for optimal quantity and quality of pulmonary specimen for tumor staging and molecular analysis
- Describe the roles and relationships of biopsy, molecular testing and therapeutic approaches for NSCLC
- Summarize the mechanisms of action, safety-efficacy profiles, tolerability and side effects of available and evolving therapies for EGFR-positive NSCLC
- Integrate pathological data and prior treatment when establishing first-line and subsequent therapy for patients with EGFR-positive NSCLC
- Physicians — maximum of 1.0 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation.
Jamie A. Chaft, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Laura Tafe, MD
Assistant Professor of Pathology
Assistant Director of Molecular Pathology
Dartmouth-Hitchcock Medical Center
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Enquiring Minds. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Consulting fees: AstraZeneca, Clovis Oncology, Genentech
- Contracted Research: AstraZeneca
- Hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following Enquiring Minds writer, Emma Hitt, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser, this list includes the current versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, Real Networks Real One Player and an Articulate Mobile Player https://itunes.apple.com/us/app/articulate-mobile-player/id505546381
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.